Yaya Capital

NeuralMed is a healthcare startup that leverages artificial intelligence to enhance medical examinations and decision-making processes. The company specializes in analyzing unstructured data from various sources to create a comprehensive and reliable data matrix. Its proprietary algorithms enable the organization of patient flow by criticality, assisting healthcare professionals in identifying pathologies and structuring reports through the analysis of free text and images. By providing real-time insights, NeuralMed's solutions not only improve diagnostic accuracy but also reduce costs for healthcare institutions. The technology is designed for seamless integration into existing systems, promoting higher user adherence and facilitating better patient care.

XP Health is a health tech startup founded in 2019 by Antonio Moraes and James Wong, specializing in an AI-powered vision benefits platform. The platform is designed to enhance vision care for employees and their families by offering a virtual-first approach that integrates seamlessly with existing vision insurance plans. Utilizing advanced machine learning and facial recognition technology, XP Health recommends eyewear frames from leading designers such as Tom Ford and Ray-Ban with high accuracy. The service includes features like online vision acuity tests, prescription renewals, and access to in-person eye exams, ensuring comprehensive vision care at reduced costs. XP Health collaborates with companies like Chegg, Zenefits, and Sequoia Consulting Group to provide these innovative benefits, striving to improve the overall accessibility and quality of vision care.

ISA is a digital-first home healthcare provider harnessing technology to bring care directly to patients' home, providing higher quality services at a fraction of the cost. Currently, ISA offers outpatient care, lab work services and immunizations. We are aiming to be the largest non-hospital healthcare company in Latam, by providing access to affordable healthcare services for millions of people through the decentralization of care.

Endpoint Health, Inc. is a precision immunology company based in Palo Alto, California, with additional offices in Michigan and Illinois. Founded in 2018, the company focuses on researching and developing therapies that integrate therapeutics, companion diagnostics, and artificial intelligence. Its mission is to enhance patient outcomes, particularly for individuals suffering from critical illnesses such as sepsis, acute respiratory distress syndrome, and COVID-19. By utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health aims to identify and match effective therapies with patients who are most likely to benefit from them, moving beyond traditional one-size-fits-all approaches in drug development. Through this strategy, the company seeks to deliver personalized treatments that can significantly improve the health outcomes of patients with autoimmune and inflammatory conditions.

Klivo Health is a healthtech company focused on improving the quality of life for individuals with chronic diseases. The company operates a patient management platform designed to empower users to manage their health more effectively. This platform offers real-time monitoring of medical conditions, facilitates the transmission of blood glucose information, and provides answers to inquiries related to clinical conditions and dietary concerns. By enabling healthcare professionals to access vital patient data, Klivo Health aims to enhance clinical outcomes for those living with chronic conditions, aligning with its mission to add life to years rather than simply extending lifespan. For additional information, interested parties can submit inquiries through the company's website.

Endpoint Health, Inc. is a precision immunology company based in Palo Alto, California, with additional offices in Michigan and Illinois. Founded in 2018, the company focuses on researching and developing therapies that integrate therapeutics, companion diagnostics, and artificial intelligence. Its mission is to enhance patient outcomes, particularly for individuals suffering from critical illnesses such as sepsis, acute respiratory distress syndrome, and COVID-19. By utilizing its proprietary AI-powered platform, OMNAI, Endpoint Health aims to identify and match effective therapies with patients who are most likely to benefit from them, moving beyond traditional one-size-fits-all approaches in drug development. Through this strategy, the company seeks to deliver personalized treatments that can significantly improve the health outcomes of patients with autoimmune and inflammatory conditions.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.